MindMaze Therapeutics Holding (RLFTF)

[Joe Kaplan]

https://twitter.com/search?q=Relief%20Therapeutics&src=typed_query&f=live

GENEVA, SWITZERLAND / ACCESSWIRE / April 5, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief Therapeutics" or the "Company"), a biopharmaceutical company committed to advancing treatment paradigms to benefit the lives of patients living with rare diseases, today announced that Nermeen Varawalla, M.D., Ph.D., chief medical officer, will depart the Company in the second quarter of 2023 to pursue other opportunities. The medical affairs team will report to Paolo Galfetti, chief operating officer at Relief Therapeutics, until a replacement is hired. Clinical development and regulatory responsibilities will continue to be supported by consultants already contracted with the Company.

"We have established strong medical affairs and research and development teams that will continue to serve us well as we focus our resources to advance our metabolic, connective tissue and pulmonary rare disease programs forward," said Jack Weinstein, chief executive officer at Relief Therapeutics. "We have moved our pipeline through several important milestones over the past year, and we appreciate Nermeen's contributions to those efforts. We wish Nermeen success in her future endeavors."